A randomized, double-blind, parallel-group single-dose study to evaluate the pharmacokinetic, safety, immunogenicity and tolerability of MSB11456 versus its US reference product after a single intravenous infusion in healthy volunteers
Latest Information Update: 26 Jul 2023
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms APTURA II
- 21 Jul 2023 According to a Fresenius Kabi Media Release, MSB11456, has received a positive recommendation for a marketing authorization from the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP).
- 14 Nov 2022 Results presented at the ACR Convergence 2022
- 09 Sep 2021 New trial record